4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics total assets
Total assets on the balance sheet at the end of each period.
4D Molecular Therapeutics's total assets was $428.75M at Sep 30, 2026. For fiscal 2025 it was $566.71M, up 1.1% from the year before. The highest annual figure on record is $566.71M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $566.71M | +1.1% |
| FY2024 | Dec 31, 2024 | $560.38M | +64.9% |
| FY2023 | Dec 31, 2023 | $339.89M | +29.8% |
| FY2022 | Dec 31, 2022 | $261.85M | -25.9% |
| FY2021 | Dec 31, 2021 | $353.49M | +22.6% |
| FY2020 | Dec 31, 2020 | $288.33M | +395.1% |
| FY2019 | Dec 31, 2019 | $58.23M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $428.75M | +1.1% |
| Q2 FY2026 | Jun 30, 2026 | $492.62M | +4.0% |
| Q1 FY2026 | Mar 31, 2026 | $512.91M | -0.5% |
| Q4 FY2025 | Dec 31, 2025 | $566.71M | +1.1% |
| Q3 FY2025 | Sep 30, 2025 | $423.98M | -29.8% |
| Q2 FY2025 | Jun 30, 2025 | $473.64M | -23.6% |
| Q1 FY2025 | Mar 31, 2025 | $515.73M | -18.1% |
| Q4 FY2024 | Dec 31, 2024 | $560.38M | +64.9% |
| Q3 FY2024 | Sep 30, 2024 | $604.03M | +67.0% |
| Q2 FY2024 | Jun 30, 2024 | $620.12M | +75.9% |
| Q1 FY2024 | Mar 31, 2024 | $629.88M | +158.1% |
| Q4 FY2023 | Dec 31, 2023 | $339.89M | +29.8% |
| Q3 FY2023 | Sep 30, 2023 | $361.61M | +29.1% |
| Q2 FY2023 | Jun 30, 2023 | $352.50M | +16.4% |
| Q1 FY2023 | Mar 31, 2023 | $244.02M | -24.9% |
| Q4 FY2022 | Dec 31, 2022 | $261.85M | -25.9% |
| Q3 FY2022 | Sep 30, 2022 | $280.16M | +16.4% |
| Q2 FY2022 | Jun 30, 2022 | $302.94M | +18.8% |
| Q1 FY2022 | Mar 31, 2022 | $324.93M | +20.3% |
| Q4 FY2021 | Dec 31, 2021 | $353.49M | +22.6% |
| Q3 FY2021 | Sep 30, 2021 | $240.62M | +313.2% |
| Q2 FY2021 | Jun 30, 2021 | $254.93M | – |
| Q1 FY2021 | Mar 31, 2021 | $270.11M | – |
| Q4 FY2020 | Dec 31, 2020 | $288.33M | – |
| Q4 FY2019 | Dec 31, 2019 | $58.23M | – |
See a number that looks wrong?